80岁以上人群他汀类药物的启用与减停:队列研究
该队列研究基于英国临床实践研究数据链212566名80岁及以上参与者,估算他汀启用与减停率。他汀使用率从2001-5年的9.9%升至2011-15年的49.3%;减停率随年龄和衰弱程度增加,百岁老人达每年17.8%。结论提示需更好证据指导≥80岁人群他汀使用与停药。
要点
- 80岁以上他汀使用率从2001-5年9.9%升至2011-15年49.3%。
- 他汀减停率随年龄和衰弱程度增加,百岁老人达每年17.8%。
- 减停率在初级预防中略高于二级预防。
核心结论
- 80岁以上人群他汀使用增加,但减停常见且随年龄和衰弱程度增加。
研究设计与样本
- 基于英国临床实践研究数据链的队列研究,纳入212566名80岁及以上参与者,采用时间至事件框架并将死亡作为竞争风险。
主要发现
- 他汀使用率从2001-5年的9.9%上升至2011-15年的49.3%。
- 从未使用者中他汀启用率总体为每年2.4%(95%CI 2.2-2.6%),并随年龄下降。
- 当前使用者中他汀减停率总体为每年5.6%(95%CI 5.4-5.9%),随年龄增加,百岁老人达每年17.8%(95%CI 6.7-28.9%)。
- 减停率在初级预防中为每年6.5%,高于二级预防的每年5.2%(P < 0.001)。
- 减停率随衰弱程度增加,fit参与者为每年5.0%,severe frailty为7.1%(P < 0.001)。
临床怎么用
- 对80岁以上患者启动他汀需权衡证据局限性,尤其考虑年龄与衰弱程度。
- 在衰弱或高龄患者中,他汀减停是常见临床实践,可结合预防类型个体化决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: statin use over the age of 80 years is weakly evidence-based. This study aimed to estimate rates of statin inception and deprescribing by frailty level in people aged 80 years or older. METHODS: a cohort of 212,566 participants aged ≥80 years was sampled from the UK Clinical Practice Research Datalink. Statin inception was defined as a first-ever prescription in a non-statin user; deprescribing was defined as a last ever statin prescription more than 6 months before the end of participant records. Rates were estimated in a time-to-event framework allowing for mortality as a competing risk. Co-variates were age, gender, frailty category and prevention type. RESULTS: prevalent statin use increased from 2001-5 (9.9%) to 2011-15 (49.3%). Inception of statins in never-users was low overall at 2.4% per year (95% confidence interval (CI) 2.2-2.6%) and declined with age. Deprescribing of statins in current users occurred at a rate of 5.6% (95% CI 5.4-5.9%) per year overall and increased with age, reaching 17.8% per year (95% CI 6.7-28.9%) among centenarians. Deprescribing was slightly higher for primary prevention (6.5% per year) than secondary prevention (5.2% per year) indications (P < 0.001). Deprescribing increased with frailty level being 5.0% per year in 'fit' participants and 7.1% in 'severe' frailty (P < 0.001). CONCLUSIONS: statin use has increased in the over 80s but deprescribing is common and increases with age and frailty level. These paradoxical findings highlight a need for better evidence to inform statin use and discontinuation for people aged ≥80 years.
引用
- Gulliford M, Ravindrarajah R, Hamada S, et al. Inception and deprescribing of statins in people aged over 80 years: cohort study. Age Ageing. 2017. PMID: 29088364. doi:10.1093/ageing/afx100
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。